Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Shots:The biopharma industry saw numerous deal terminations in 2021. Clinical and regulatory results, change of control limitations, and strategic reprioritizations were among the most common reasons for deal termination.SOBI and Advent's acquisition agreement in 2021 ranked first under which Advent International offered to acquire SOBI. The second position goes to Galapagos’ development and…

ByPrince GiriMarch 10, 2022

INSIGHTS+

Insights+: The US FDA New Drug Approvals in May 2021

The US FDA has approved 4 NDAs and 1 BLAs in 2021, leading to treatments for patients and advances in the health care industry.The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 29 novel products in 2021.Additionally, last year in 2020, the US FDA…

BySenior EditorJune 17, 2021

Top 20 Biopharma Deal Terminations of 2021 Based on Total Deal Value

Insights+: The US FDA New Drug Approvals in May 2021

Contact US

OUR INFORMATION

FOLLOW US